Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma

Melanoma Research

Volumn 26, Issue 2, 2016, Pages 202-204

  Kong, Benjamin Y ^a,b   Micklethwaite, Kenneth P ^a,b   Swaminathan, Sanjay ^a,b   Kefford, Richard F ^a,b,c   Carlino, Matteo S ^a,b,c  

^a WESTMEAD HOSPITAL   (Australia)

^b University of Sydney   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

Author keywords

Autoimmune; Hemolytic anemia; Ipilimumab; Melanoma; Nivolumab; PD 1; T cells

Indexed keywords

ALLOANTIBODY; BILIRUBIN; CORTICOSTEROID; ERYTHROCYTE ANTIBODY; HAPTOGLOBIN; HEMOGLOBIN; IPILIMUMAB; LACTATE DEHYDROGENASE; NIVOLUMAB; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CANCER PATIENT; CASE REPORT; COOMBS TEST; CORTICOSTEROID THERAPY; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FATIGUE; HEMOLYSIS; HUMAN; IMMUNOLOGICAL TOLERANCE; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; VERY ELDERLY; BLOOD; CHEMICALLY INDUCED; IMMUNOLOGY; MELANOMA;

AGED, 80 AND OVER; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; HUMANS; IPILIMUMAB; ISOANTIBODIES; MALE; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84954498344     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000232     Document Type: Article

References (13)

1. du Rusquec P, Saint-Jean M, Brocard A, Peuvrel L, Khammari A, Quéreux G, Dréno B. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. J Immunother 2014; 37:348-350.
2. Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 2009; 58:1351-1353.
3. Simeone E, Grimaldi AM, Esposito A, Curvietto M, Palla M, Paone M, et al. Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep 2014; 8:240.
4. Wang C, Thudium KB, Han M,Wang XT, Huang H, Feingersh D, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2014; 2:846-856.
5. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8:765-772.
6. Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol 1998; 10:1563-1572.
7. Thibult ML, Mamessier E, Gertner-Dardenne J, Pastor S, Just-Landi S, Xerri L, et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol 2013; 25:129-137.
8. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616-622.
9. Elimelakh M, Dayton V, Park KS, Gruessner AC, Sutherland D, Howe RB, et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica 2007; 92:1029-1036.
10. Jourdan E, Topart D, Richard B, Jourdan J, Sotto A. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder. Leuk Lymphoma 2003; 44:889-890.
11. Kako S, Kanda Y, Oshima K, Nishimoto N, Sato H, Watanabe T, et al. Late onset of autoimmune hemolytic anemia and pure red cell aplasia after allogeneic hematopoietic stem cell transplantation using in vivo alemtuzumab. Am J Hematol 2008; 83:247-249.
12. Mqadmi A, Zheng X, Yazdanbakhsh K. CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia. Blood 2005; 105:3746-3748.
13. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-264.